Ammar Qoubaitary, MD
Endocrinology, Diabetes & Metabolism · San Ramon, CANPI 1851346977
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $426,982 of the $507,695 with a category attached, or 84.1%. 60 manufacturers reported payments, led by Novo Nordisk at 59.4% of the total. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,641 payments — averaging $309.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$302K
- Johnson & Johnson$64K
- Lilly USA, LLC$29K
- Boehringer Ingelheim$25K
- AstraZeneca$24K
- Dexcom, Inc.$15K
- plus $48K from 54 others
What the payments were for
- Consulting fees$16,8783%
- Speaking & faculty fees$426,98284%
- Travel & lodging$24,2165%
- Food & beverage$38,0107%
- Education$1,6100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$139,436
- Ozempic$121,079
- INVOKANA$62,640
- JARDIANCE$46,991
- FARXIGA$22,237
- DEXCOM G7 GSS (161)$14,372
- DEXCOM STELO GLUCOSE BIOSENSOR$14,266
- Tirosint$9,721
- Vascepa$8,124
- Tresiba$6,163
- EVENITY$4,861
- DISEASE STATE$2,655
- Korlym$1,687
- CRF$1,313
- iLet Bionic Pancreas$1,206
- TEPEZZA$658
- Prolia$425
- Tymlos$340
- Repatha$247
- NURTEC ODT$229
How this compares
$507,695 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 411 | $754,768 |
| JardianceEmpagliflozin | 274 | $392,212 |
| RybelsusSemaglutide | 151 | $287,940 |
| FarxigaDapagliflozin Propanediol | 137 | $179,934 |
| TrulicityDulaglutide | 97 | $159,043 |
| MounjaroTirzepatide | 103 | $124,105 |
| TradjentaLinagliptin | 113 | $112,788 |
| Tresiba Flextouch U-200Insulin Degludec | 55 | $66,443 |
| JanuviaSitagliptin Phosphate | 41 | $57,227 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 37 | $40,264 |
| VascepaIcosapent Ethyl | 41 | $29,758 |
| Tresiba Flextouch U-100Insulin Degludec | 36 | $26,240 |
| Repatha SureclickEvolocumab | 16 | $18,570 |
| SynthroidLevothyroxine Sodium | 175 | $17,197 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 37 | $14,783 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $301,746 | $1,042,708562 claims |
| Boehringer IngelheimJardiance, Tradjenta | $25,426 | $505,000387 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $29,428 | $283,149200 claims |
| AstraZenecaFarxiga | $24,257 | $179,934137 claims |
| MerckJanuvia, Janumet Xr | $332 | $72,01078 claims |
| AbbVieSynthroid | $933 | $17,197175 claims |
| Antares Pharma, Inc.Xyosted | $286 | $11,73220 claims |
| IBSA Pharma Inc.Tirosint | $8,868 | $5,65222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in San Ramon
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.